



April 24, 2012

The National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sirs,

Sub: Disclosure pursuant to Clause 36 of the Listing Agreement.

Enclosed is a press release as regards setting-up of a state-of-the-art Greenfield Formulations manufacturing facility at the Special Economic Zone, MIHAN, Nagpur.

The above may be considered as a disclosure pursuant to Clause 36 of the Listing Agreement.

Thanking you,

Yours faithfully,
For **LUPIN LIMITED**

R. V. SATAM
COMPANY SECRETARY & COMPLIANCE OFFICER

Encl.: a/a.

**LUPIN**

BSE : 500257

NSE: Lupin

REUTERS: LUPN.BO

BLOOMBERG: LPC IN

Lupin To Set Up New Formulations Manufacturing Facility In MIHAN

Mumbai / Baltimore, April 24, 2012: Pharmaceutical major Lupin Ltd., announced today that it has broken ground to set up a new state-of-the-art formulation manufacturing facility at the Special Economic Zone (SEZ), MIHAN, Nagpur. The Greenfield plant will take close to a year to being set up.

Lupin today operates 11 world class manufacturing facilities spread across India & Japan. Almost all of Lupin's facilities have been inspected by leading regulators like the US FDA, UK MHRA, WHO, Australian TGA, and Japan's MHLW.

Commenting on the development, Mr. Nilesh Gupta, Group President & Executive Director, Lupin Limited, said, "The strategic investment in the new formulation facility at MIHAN is not only in keeping with the consistent growth that Lupin has witnessed across key markets like the U.S. but it would also ensure that our manufacturing capacities are attuned to future demand. Nagpur as a location has strategic proximity to key metros as well as international aviation routes. We are happy to be here at MIHAN and to be able to contribute to the development of the local economy."

About Lupin Limited

Headquartered in Mumbai, India, Lupin is an innovation led transnational pharmaceutical company producing a wide range of generic and branded formulations and APIs. The Company today has significant presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAID space in addition to holding global leadership positions in the Anti-TB and Cephalosporin segments.

Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health), the only Asian company to achieve that distinction. The company is also the fastest growing top 10 pharmaceutical player in India, Japan and South Africa (IMS).

For the financial year ended March 2011, Lupin's Consolidated Revenues and Profit after Tax were Rs.57,068 Million (USD 1.28 Billion) and Rs. 8,626 Million (USD 193 Million) respectively.

Please visit <http://www.lupinworld.com> for more information on Lupin Ltd.

For more information, please contact:

Shamsher Gorawara
Head - Corporate Communications
Lupin Limited
Ph: +91 98 20 338 555
Email: shamshergorawara@lupinpharma.com

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:

This release contains forward looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Many of these risks, uncertainties and other factors include failure of clinical trials, delays in development, registration and product approvals, changes in the competitive environment, increased government control over pricing, fluctuations in the capital and foreign exchange markets and the ability to maintain patent and other intellectual property protection. The information presented in this release represents management's expectations and intentions as of this date. Lupin expressly disclaims any obligation to update the information presented in this release.